Renaissance Capital logo

Forma Therapeutics Priced, Nasdaq: FMTX

Phase 1 biotech developing therapies for SCD and hematologic diseases.

Industry: Health Care

First Day Return: +95.0%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our drug discovery expertise has generated a pipeline of small molecule product candidates focused on indications with significant unmet patient need. Our pipeline consists of seven product candidates, two of which we are pursuing as core product candidates for development, FT-4202 for the treatment of sickle cell disease, or SCD, and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. Our lead core product candidate, FT-4202, is a novel, oral, once-daily, potentially disease-modifying therapy initially being studied for the treatment of SCD, one of the most common single-gene disorders in the world. FT-4202 is a potent activator of pyruvate kinase-R, or PKR, designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. We are evaluating FT-4202 in a multi-center, placebo-controlled Phase I trial in SCD patients ages 12 years and older. We completed the healthy volunteer portion of the trial in May 2019 and presented data at the 2019 American Society of Hematology meeting demonstrating the tolerability and proof of mechanism of FT-4202 in healthy volunteers. We reported data from a single dose cohort in seven SCD patients in May 2020.
more less
IPO Data
IPO File Date 05/29/2020
Offer Price $20.00
Price Range $16.00 - $18.00
Offer Shares (mm) 13.9
Deal Size ($mm) $278
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/18/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $278
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Watertown, MA, United States
Founded 2007
Employees at IPO 77
Website www.formatherapeutics.com

Forma Therapeutics (FMTX) Performance